{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T09:46:58Z","timestamp":1719481618201},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T00:00:00Z","timestamp":1380067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00535-013-0884-0","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T02:06:11Z","timestamp":1380074771000},"page":"1253-1263","source":"Crossref","is-referenced-by-count":4,"title":["Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C"],"prefix":"10.1007","volume":"49","author":[{"given":"Nobuhiro","family":"Aizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirayuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,25]]},"reference":[{"key":"884_CR1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med."},{"key":"884_CR2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","volume":"140","author":"AS Lok","year":"2011","unstructured":"Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140:840\u20139.","journal-title":"Gastroenterology"},{"key":"884_CR3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2169\/internalmedicine.47.1087","volume":"47","author":"M Hirakawa","year":"2008","unstructured":"Hirakawa M, Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Hosaka T, et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med. 2008;47:637\u20131643.","journal-title":"Intern Med"},{"key":"884_CR4","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/ajg.2010.294","volume":"105","author":"CM Fern\u00e1ndez-Rodr\u00edguez","year":"2010","unstructured":"Fern\u00e1ndez-Rodr\u00edguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rinc\u00f3n D, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105:2164\u201372.","journal-title":"Am J Gastroenterol"},{"key":"884_CR5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1872-034X.2012.00984.x","volume":"42","author":"LS Qu","year":"2012","unstructured":"Qu LS, Chen H, Kuai XL, Xu ZF, Jin F, Zhou GX. Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: a meta-analysis of randomized controlled trials. Hepatol Res. 2012;42:782\u20139.","journal-title":"Hepatol Res."},{"key":"884_CR6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958\u201365.","journal-title":"Lancet"},{"key":"884_CR7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346\u201355.","journal-title":"Ann Intern Med"},{"key":"884_CR8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u201382.","journal-title":"N Engl J Med"},{"key":"884_CR9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580\u201393.","journal-title":"N Engl J Med"},{"key":"884_CR10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2796.2009.02130.x","volume":"266","author":"EG Giannini","year":"2009","unstructured":"Giannini EG, Basso M, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med. 2009;266:537\u201346.","journal-title":"J Intern Med"},{"key":"884_CR11","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/00365520802245395","volume":"43","author":"E Syed","year":"2008","unstructured":"Syed E, Rahbin N, Weiland O, Carlsson T, Oksanen A, Birk M, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol. 2008;43:1378\u201386.","journal-title":"Scand J Gastroenterol"},{"key":"884_CR12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0149-2918(11)00022-1","volume":"32","author":"E Vezali","year":"2010","unstructured":"Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010;32:2117\u201338.","journal-title":"Clin Ther"},{"key":"884_CR13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","volume":"123","author":"JG McHutchison","year":"2002","unstructured":"McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061\u20139.","journal-title":"Gastroenterology"},{"key":"884_CR14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2893.2009.01116.x","volume":"16","author":"T Oze","year":"2009","unstructured":"Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, et al. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat. 2009;16:578\u201385.","journal-title":"J Viral Hepat."},{"key":"884_CR15","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","volume":"124","author":"MW Russo","year":"2003","unstructured":"Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711\u20139.","journal-title":"Gastroenterology"},{"key":"884_CR16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1478-3231.2012.02798.x","volume":"32","author":"EG Giannini","year":"2012","unstructured":"Giannini EG, Marenco S, Fazio V, Pieri G, Savarino V, Picciotto A. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int. 2012;32:1113\u201339.","journal-title":"Liver Int."},{"key":"884_CR17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1440-1746.2011.06870.x","volume":"27","author":"T Akahoshi","year":"2012","unstructured":"Akahoshi T, Tomikawa M, Kawanaka H, Furusyo N, Kinjo N, Tsutsumi N, et al. Laparoscopic splenectomy with IFN therapy in one hundred HCV-cirrhotic patients with hypersplenism and thrombocytopenia. J Gastroenterol Hepatol. 2012;27:286\u201390.","journal-title":"J Gastroenterol Hepatol"},{"key":"884_CR18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00464-009-0653-6","volume":"24","author":"T Akahoshi","year":"2010","unstructured":"Akahoshi T, Tomikawa M, Korenaga D, Ikejiri K, Saku M, Takenaka K. Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc. 2010;24:680\u20135.","journal-title":"Surg Endosc"},{"key":"884_CR19","first-page":"488","volume":"17","author":"K Ikezawa","year":"2010","unstructured":"Ikezawa K, Naito M, Yumiba T, Iwahashi K, Onishi Y, Kita H, et al. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat. 2010;17:488\u201392.","journal-title":"J Viral Hepat."},{"key":"884_CR20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1872-034X.2008.00481.x","volume":"39","author":"D Morihara","year":"2009","unstructured":"Morihara D, Kobayashi M, Ikeda K, Kawamura Y, Saneto H, Yatuji H, et al. Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatol Res. 2009;39:439\u201347.","journal-title":"Hepatol Res."},{"key":"884_CR21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s00535-011-0407-9","volume":"46","author":"H Tahara","year":"2011","unstructured":"Tahara H, Takagi H, Sato K, Shimada Y, Tojima H, Hirokawa T, et al. A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. J Gastroenterol. 2011;46:1010\u20139.","journal-title":"J Gastroenterol"},{"key":"884_CR22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1872-034X.2008.00357.x","volume":"38","author":"Y Miyake","year":"2008","unstructured":"Miyake Y, Ando M, Kaji E, Toyokawa T, Nakatsu M, Hirohata M. Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res. 2008;38:980\u20136.","journal-title":"Hepatol Res."},{"key":"884_CR23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/00042737-200511000-00002","volume":"17","author":"JR Foruny","year":"2005","unstructured":"Foruny JR, Bl\u00e1zquez J, Moreno A, B\u00e1rcena R, Gil-Grande L, Quereda C, et al. Safe use of pegylated interferon\/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol. 2005;17:1157\u201364.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"884_CR24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199601113340203","volume":"334","author":"N Enomoto","year":"1996","unstructured":"Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77\u201381.","journal-title":"N Engl J Med"},{"key":"884_CR25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000086064","volume":"48","author":"N Akuta","year":"2005","unstructured":"Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372\u201380.","journal-title":"Intervirology"},{"key":"884_CR26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105\u20139.","journal-title":"Nat Genet"},{"key":"884_CR27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1478-3231.2011.02571.x","volume":"31","author":"K Hayashi","year":"2011","unstructured":"Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, et al. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver Int. 2011;31:1359\u201365.","journal-title":"Liver Int."},{"key":"884_CR28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2010.07.037","volume":"54","author":"M Kurosaki","year":"2011","unstructured":"Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 2011;54:439\u201348.","journal-title":"J Hepatol"},{"key":"884_CR29","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1872-034X.2012.01013.x","volume":"42","author":"H Saito","year":"2012","unstructured":"Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, et al. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. Hepatol Res. 2012;42:958\u201365.","journal-title":"Hepatol Res."},{"key":"884_CR30","doi-asserted-by":"crossref","unstructured":"Ikeda N, Imanishi H, Aizawa N, Tanaka H, Iwata Y, Enomoto H, et al. A nationwide survey in Japan regarding splenectomy\/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count. Hepatol Res. 2013. doi: 10.1111\/hepr.12184 . (Epub ahead of print).","DOI":"10.1111\/hepr.12184"},{"key":"884_CR31","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","volume":"357","author":"JG McHutchison","year":"2007","unstructured":"McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227\u201336.","journal-title":"N Engl J Med"},{"key":"884_CR32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","volume":"204","author":"K Chayama","year":"2011","unstructured":"Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204:84\u201393.","journal-title":"J Infect Dis"},{"key":"884_CR33","doi-asserted-by":"crossref","unstructured":"Andrew J. Muir, Mitchell L. Shiffman, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822\u201332.","DOI":"10.1002\/hep.23743"},{"key":"884_CR34","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural Protein 5A Inhibitor, BMS-790052, and the Nonstructural Protein 3 Protease Inhibitor, BMS-650032, in Hepatitis C Virus Genotype 1b-Infected Null Responders. Hepatology. 2012;55:742\u20138.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-013-0884-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-013-0884-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-013-0884-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T22:51:53Z","timestamp":1553640713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-013-0884-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,25]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s00535-013-0884-0","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,25]]}}}